{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:07:51Z","timestamp":1791216471936,"version":"4.1.0"},"reference-count":214,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,3,25]],"date-time":"2023-03-25T00:00:00Z","timestamp":1679702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Myocarditis associated with the use of immune checkpoint inhibitors (ICI) is a rare manifestation of their cardiotoxicity, but is characterized by a high mortality rate. A literature search was conducted using PubMed using keywords, which resulted in the selection of 679 scientific works, from which 160 articles that described 244 clinical cases were selected. The median age of the patients was 67 years (IQR, 60\u201374). The median time from the start of ICI therapy to the development of the first adverse symptoms was 21 days (IQR, 14\u201338.3). In 37% of cases, myocarditis developed after the first administration of ICI. Cardiac symptoms were present in 47.1% of cases, neuromuscular symptoms in 30.3%, and other symptoms in 12.6%, while myocarditis was asymptomatic in 10.1% of cases. New changes in the electrocardiograms were detected in 85.1% of patients compared to the initial data. A high incidence of complete atrioventricular block (25.4%), right bundle branch block (18.4%), ventricular tachycardia (13%), and sinus tachycardia (12%) were noted. In 97% of the cases, the patients received prednisolone or methylprednisolone therapy. When using ICI, special attention should be paid to the early detection of possible cardiotoxicity by analyzing the condition and function of the myocardium before treatment and its dynamics.<\/jats:p>","DOI":"10.3390\/diagnostics13071243","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T01:38:36Z","timestamp":1679881116000},"page":"1243","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Immune Checkpoint Inhibitors-Related Myocarditis: A Review of Reported Clinical Cases"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7658-7846","authenticated-orcid":false,"given":"Liudmila","family":"Zotova","sequence":"first","affiliation":[{"name":"Department of Hospital Therapy with a Course of Medical and Social Expertise, Federal State Budgetary Educational Institution of Higher Education \u201cRyazan State Medical University named after Academician I.P. Pavlova\u201d of the Ministry of Health of the Russian Federation, Ryazan 390026, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3389\/fimmu.2017.00829","article-title":"Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models","volume":"8","author":"Decker","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1200\/EDBK_240837","article-title":"Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy not Work for all Patients?","volume":"39","author":"Fares","year":"2019","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.3389\/fimmu.2019.02965","article-title":"The Intriguing History of Cancer Immunotherapy","volume":"10","author":"Dobosz","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s40265-022-01761-9","article-title":"Cadonilimab: First Approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"312","DOI":"10.2174\/22123970MTE09MDYg0","article-title":"Current Status and Prospects of Camrelizumab, A Humanized Antibody Against Programmed Cell Death Receptor 1","volume":"16","author":"Song","year":"2021","journal-title":"Recent Patents Anti-Cancer Drug Discov."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"695512","DOI":"10.3389\/fonc.2021.695512","article-title":"Efficacy and Safety of Camrelizumab Monotherapy and Combination Therapy for Cancers: A Systematic Review and Meta-Analysis","volume":"11","author":"Wang","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_8","unstructured":"(2023, February 10). Investor.lilly. Available online: https:\/\/investor.lilly.com\/news-releases\/news-release-details\/innovent-and-lilly-announce-successful-expansion-sintilimab."},{"key":"ref_9","unstructured":"(2023, February 13). BeiGene. Available online: https:\/\/ir.beigene.com\/news\/china-nmpa-approves-tislelizumab-for-patients-with-second-line-esophageal-squamous-cell-carcinoma\/50b0ad83-47cf-46e7-a6fd-53ccc04058f2\/."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"730666","DOI":"10.3389\/fimmu.2021.730666","article-title":"Toripalimab: The First Domestic Anti-Tumor PD-1 Antibody in China","volume":"12","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Yan, J., Zhang, Y., Zhang, J.-P., Liang, J., Li, L., and Zheng, L. (2013). Tim-3 Expression Defines Regulatory T Cells in Human Tumors. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0058006"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.immuni.2004.08.010","article-title":"Role of LAG-3 in Regulatory T Cells","volume":"21","author":"Huang","year":"2004","journal-title":"Immunity"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/ni.1674","article-title":"The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells","volume":"10","author":"Yu","year":"2008","journal-title":"Nat. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"946319","DOI":"10.3389\/fonc.2022.946319","article-title":"Can circulating PD-1, PD-L1, BTN3A1, pan-BTN3As, BTN2A1 and BTLA levels enhance prognostic power of CA125 in patients with advanced high-grade serous ovarian cancer?","volume":"12","author":"Fanale","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1158\/0008-5472.CAN-13-1504","article-title":"VISTA Is an Immune Checkpoint Molecule for Human T Cells","volume":"74","author":"Lines","year":"2014","journal-title":"Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s40425-017-0296-4","article-title":"Smoldering myocarditis following immune checkpoint blockade","volume":"5","author":"Norwood","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11912-020-0897-9","article-title":"Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls","volume":"22","author":"Darnell","year":"2020","journal-title":"Curr. Oncol. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jaccao.2020.11.012","article-title":"The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of Cardiotoxicity","volume":"3","author":"Zhang","year":"2021","journal-title":"JACC Cardio-Oncology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1146\/annurev-pharmtox-010919-023451","article-title":"Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure","volume":"61","author":"Waliany","year":"2021","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: A comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.cllc.2020.04.003","article-title":"A Population-based Study of Immunotherapy-related Toxicities in Lung Cancer","volume":"21","author":"Sangaralingham","year":"2020","journal-title":"Clin. Lung Cancer"},{"key":"ref_22","first-page":"771","article-title":"Coverage Evaluation of CTCAE for Capturing the Immune-related Adverse Events Leveraging Text Mining Technologies","volume":"2019","author":"Yu","year":"2019","journal-title":"AMIA Jt. Summits Transl. Sci. proceedings. AMIA Jt. Summits Transl. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"iv264","DOI":"10.1093\/annonc\/mdy162","article-title":"Corrections to \u201cManagement of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Haanen","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_26","unstructured":"National Cancer Institute (2023, January 07). Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Available online: https:\/\/www.meddra.org\/."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e000247","DOI":"10.1136\/esmoopen-2017-000247","article-title":"Cardiotoxicity of immune checkpoint inhibitors","volume":"2","author":"Varricchi","year":"2017","journal-title":"ESMO Open"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant Myocarditis with Combination Immune Checkpoint Blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in Patients Treated With Immune Checkpoint Inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1634\/theoncologist.2018-0130","article-title":"Immune Checkpoint Inhibitor-Associated Myocarditis","volume":"23","author":"Ganatra","year":"2018","journal-title":"Oncologist"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.117.030571","article-title":"Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor\u2013Related Cardiotoxicity","volume":"136","author":"Escudier","year":"2017","journal-title":"Circulation"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1161\/CIRCRESAHA.120.315894","article-title":"Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies","volume":"128","author":"Baik","year":"2021","journal-title":"Circ. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.3389\/fphar.2019.01350","article-title":"Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management","volume":"10","author":"Zhou","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Quagliariello, V., Passariello, M., Rea, D., Barbieri, A., Iovine, M., Bonelli, A., Caronna, A., Botti, G., De Lorenzo, C., and Maurea, N. (2020). Evidences of CTLA-4 and PD-1 Blocking Agents-Induced Cardiotoxicity in Cellular and Preclinical Models. J. Pers. Med., 10.","DOI":"10.3390\/jpm10040179"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Tay, W.T., Fang, Y.-H., Beh, S.T., Liu, Y.-W., Hsu, L.-W., Yen, C.-J., and Liu, P.-Y. (2020). Programmed Cell Death-1: Programmed Cell Death-Ligand 1 Interaction Protects Human Cardiomyocytes Against T-Cell Mediated Inflammation and Apoptosis Response In Vitro. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21072399"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/intimm\/dxq026","article-title":"PD-1 deficiency results in the development of fatal myocarditis in MRL mice","volume":"22","author":"Wang","year":"2010","journal-title":"Int. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1161\/CIRCRESAHA.106.147124","article-title":"CTLA-4 Ablation and Interleukin-12\u2013Driven Differentiation Synergistically Augment Cardiac Pathogenicity of Cytotoxic T Lymphocytes","volume":"101","author":"Love","year":"2007","journal-title":"Circ. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"634","DOI":"10.3389\/fneur.2020.00634","article-title":"Immune Checkpoint Inhibitor-Induced Myasthenia Gravis","volume":"11","author":"Huang","year":"2020","journal-title":"Front. Neurol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.21037\/tlcr-20-1095","article-title":"Pembrolizumab-induced myocarditis in a patient with malignant mesothelioma: Plasma exchange as a successful emerging therapy\u2014Case report","volume":"10","author":"Schiopu","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ejca.2018.10.025","article-title":"Presence of antibodies to striated muscle and acetylcholine receptor in association with occurrence of myasthenia gravis with myositis and myocarditis in a patient with melanoma treated with an anti\u2013programmed death 1 antibody","volume":"106","author":"Shirai","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejca.2017.11.026","article-title":"Severe ophthalmoplegia and myocarditis following the administration of pembrolizumab","volume":"91","author":"Nasr","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ajem.2021.03.005","article-title":"Immune checkpoint inhibitor-associated myasthenia gravis, myositis, and myocarditis overlap syndrome","volume":"46","author":"Lipe","year":"2021","journal-title":"Am. J. Emerg. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.lungcan.2019.06.015","article-title":"Fatal adverse events in two thymoma patients treated with anti-PD-1 immune check point inhibitor and literature review","volume":"135","author":"Konstantina","year":"2019","journal-title":"Lung Cancer"},{"key":"ref_46","first-page":"5126717","article-title":"The Terrible Triad of Checkpoint Inhibition: A Case Report of Myasthenia Gravis, Myocarditis, and Myositis Induced by Cemiplimab in a Patient with Metastatic Cutaneous Squamous Cell Carcinoma","volume":"2020","author":"Jeyakumar","year":"2020","journal-title":"Case Rep. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1080\/01676830.2018.1490439","article-title":"Pembrolizumab and epacadostat induced fatal myocarditis and myositis presenting as a case of ptosis and ophthalmoplegia","volume":"38","author":"Hellman","year":"2018","journal-title":"Orbit"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/imj.14946","article-title":"Nivolumab-associated myositis myocarditis and myasthenia and anti-striated muscle antibodies","volume":"50","author":"Fazal","year":"2020","journal-title":"Intern. Med. J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/CMR.0000000000000314","article-title":"New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma","volume":"27","author":"Behling","year":"2017","journal-title":"Melanoma Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s12328-021-01442-2","article-title":"A case of immune checkpoint inhibitor-associated myocarditis after initiation of atezolizumab plus bevacizumab therapy for advanced hepatocellular carcinoma","volume":"14","author":"Iwasaki","year":"2021","journal-title":"Clin. J. Gastroenterol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"569466","DOI":"10.3389\/fphar.2020.569466","article-title":"Case Report: Fatal Multiorgan Failure and Heterochronous Pneumonitis Following Pembrolizumab Treatment in a Patient With Large-Cell Neuroendocrine Carcinoma of Lung","volume":"11","author":"Xie","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.asjsur.2021.08.067","article-title":"A case of carrelizumab-associated immune myocarditis","volume":"45","author":"Zhao","year":"2021","journal-title":"Asian J. Surg."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/CMR.0000000000000251","article-title":"Myocarditis as an immune-related adverse event with ipilimumab\/nivolumab combination therapy for metastatic melanoma","volume":"26","author":"Mehta","year":"2016","journal-title":"Melanoma Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1080\/15563650.2017.1401079","article-title":"Fatal myocarditis and rhabdomyolysis induced by nivolumab during the treatment of type B3 thymoma","volume":"56","author":"Chen","year":"2017","journal-title":"Clin. Toxicol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"812.e1","DOI":"10.1016\/j.cjca.2018.03.007","article-title":"Late-Onset Fulminant Myocarditis With Immune Checkpoint Inhibitor Nivolumab","volume":"34","author":"Yamaguchi","year":"2018","journal-title":"Can. J. Cardiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMc1901677","article-title":"Abatacept for Severe Immune Checkpoint Inhibitor\u2013Associated Myocarditis","volume":"380","author":"Salem","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.2147\/CMAR.S185202","article-title":"Cardiac toxicity of immune-checkpoint inhibitors: A clinical case of nivolumab-induced myocarditis and review of the evidence and new challenges","volume":"11","author":"Huertas","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"ix90","DOI":"10.1093\/annonc\/mdx697.072","article-title":"Acute myocarditis and pericarditis after nivolumab treatment in patients with non-small cell lung cancer","volume":"28","author":"Sakai","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ejca.2020.02.046","article-title":"Early detection and management of immune-related myocarditis: Experience from a case with advanced squamous cell lung carcinoma","volume":"131","author":"Tu","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1093\/annonc\/mdx213","article-title":"Immune checkpoint-associated cardiotoxicity: Case report with systematic review of literature","volume":"28","author":"Chauhan","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_61","first-page":"67","article-title":"Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation","volume":"30","author":"Vazquez","year":"2019","journal-title":"Neuromuscul. Disord."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"92.e1","DOI":"10.1016\/j.cjca.2017.09.025","article-title":"Immune Checkpoint Inhibitor-Associated Myocarditis: A New Challenge for Cardiologists","volume":"34","author":"Frigeri","year":"2018","journal-title":"Can. J. Cardiol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.lungcan.2016.06.025","article-title":"Drug-induced myocarditis after nivolumab treatment in a patient with PDL1- negative squamous cell carcinoma of the lung","volume":"99","author":"Semper","year":"2016","journal-title":"Lung Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/1556-4029.13633","article-title":"Fatal Myocarditis Following Treatment with the PD-1 Inhibitor Nivolumab","volume":"63","author":"Matson","year":"2017","journal-title":"J. Forensic Sci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.repc.2019.03.013","article-title":"A case of lymphocytic myocarditis in a patient treated with an immune checkpoint inhibitor, a recent class of chemotherapy agents","volume":"41","author":"Duarte","year":"2022","journal-title":"Rev. Port. de Cardiol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2121109","DOI":"10.1080\/21645515.2022.2121109","article-title":"Long-term survival after immunotherapy and targeted therapy without chemotherapy in an elderly patient with HER2-positive gastroesophageal junction cancer: A case report","volume":"6","author":"Li","year":"2022","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.2169\/internalmedicine.9033-21","article-title":"Sick Sinus Syndrome: More Than a Needle-in-a-haystack Manifestation of Immune Checkpoint Inhibitor-associated Myocarditis","volume":"61","author":"Kadowaki","year":"2022","journal-title":"Intern. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1002\/ejhf.806","article-title":"Immune-related fulminant myocarditis in a patient receiving ipilimumab therapy for relapsed chronic myelomonocytic leukaemia","volume":"19","author":"Berg","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"ref_69","first-page":"e4869","article-title":"Nivolumab-induced Third Degree Atrioventricular Block in a Patient with Stage IV Squamous Cell Lung Carcinoma","volume":"11","author":"Bukamur","year":"2019","journal-title":"Cureus"},{"key":"ref_70","first-page":"2539493","article-title":"Severe Myositis, Myocarditis, and Myasthenia Gravis with Elevated Anti-Striated Muscle Antibody following Single Dose of Ipilimumab-Nivolumab Therapy in a Patient with Metastatic Melanoma","volume":"2019","author":"Fazel","year":"2019","journal-title":"Case Rep. Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1016\/j.jtho.2018.10.156","article-title":"Fulminant Myocarditis Caused by an Immune Checkpoint Inhibitor: A Case Report With Pathologic Findings","volume":"14","author":"Imai","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_72","first-page":"3553","article-title":"Immune checkpoint inhibitors myocarditis: Not all cases are clinically patent","volume":"38","author":"Thibault","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1159\/000479958","article-title":"Nivolumab-Induced Myocarditis Concomitant with Myasthenia Gravis","volume":"10","author":"Fukasawa","year":"2017","journal-title":"Case Rep. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1200\/JOP.18.00208","article-title":"Myocarditis with Radiotherapy and Immunotherapy in Multiple Myeloma","volume":"14","author":"Chang","year":"2018","journal-title":"J. Oncol. Pract."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1161\/01.RES.68.6.1713","article-title":"Left ventricular myocardial edema. Lymph flow, interstitial fibrosis, and cardiac function","volume":"68","author":"Allen","year":"1991","journal-title":"Circ. Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ejca.2019.09.009","article-title":"A closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapies","volume":"124","author":"Guo","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"250","DOI":"10.21037\/atm.2020.01.79","article-title":"Myositis-myasthenia gravis overlap syndrome complicated with myasthenia crisis and myocarditis associated with anti-programmed cell death-1 (sintilimab) therapy for lung adenocarcinoma","volume":"8","author":"Xing","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"16","DOI":"10.21037\/cco.2020.03.08","article-title":"A retrospective study of immune checkpoint inhibitor-associated myocarditis in a single center in China","volume":"9","author":"Wang","year":"2020","journal-title":"Chin. Clin. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1159\/000507278","article-title":"Associated Myocarditis: A Predictive Factor for Response?","volume":"13","author":"Shalata","year":"2020","journal-title":"Case Rep. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ehjcr\/ytaa126","article-title":"Fatal cerebral haemorrhagic infarction due to left ventricular thrombus after healing of immune checkpoint inhibitor-associated myocarditis","volume":"4","author":"Sakai","year":"2020","journal-title":"Eur. Heart J. Case Rep."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jaccao.2020.05.022","article-title":"Late-Onset Giant Cell Myocarditis Due to Enterovirus During Treatment With Immune Checkpoint Inhibitors","volume":"2","author":"Mirabel","year":"2020","journal-title":"JACC Cardio-Oncology"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"101508","DOI":"10.1016\/j.eucr.2020.101508","article-title":"Myocarditis and myasthenia gravis by combined nivolumab and ipilimumab immunotherapy for renal cell carcinoma: A case report of successful management","volume":"34","author":"Yanase","year":"2020","journal-title":"Urol. Case Rep."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.cjco.2020.11.004","article-title":"Plasma Exchange for Immune Checkpoint Inhibitor\u2013Induced Myocarditis","volume":"3","author":"Yogasundaram","year":"2020","journal-title":"CJC Open"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e007524","DOI":"10.1161\/CIRCHEARTFAILURE.120.007524","article-title":"Subclinical Myocarditis After Combination Immune Checkpoint Inhibitor Therapy","volume":"14","author":"Giblin","year":"2021","journal-title":"Circ. Heart Fail."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2169\/internalmedicine.5412-20","article-title":"Asymptomatic Immune Checkpoint Inhibitor-associated Myocarditis","volume":"60","author":"Tanabe","year":"2021","journal-title":"Intern. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jaccao.2021.01.004","article-title":"Myocarditis Surveillance With High-Sensitivity Troponin I During Cancer Treatment With Immune Checkpoint Inhibitors","volume":"3","author":"Waliany","year":"2021","journal-title":"JACC Cardio-Oncology"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1042\/CS20200331","article-title":"Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"135","author":"Baik","year":"2021","journal-title":"Clin. Sci."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1093\/eurheartj\/ehab319","article-title":"Management of immune checkpoint inhibitor myocarditis: A serial cardiovascular magnetic resonance T2 mapping approach","volume":"42","author":"Ida","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1186\/s13256-021-02934-y","article-title":"Fulminant myocarditis induced by immune checkpoint inhibitor nivolumab: A case report and review of the literature","volume":"15","author":"Wang","year":"2021","journal-title":"J. Med. Case Rep."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40959-021-00114-x","article-title":"Immune checkpoint inhibitor-induced myocarditis in cancer patients: A case report and review of reported cases","volume":"7","author":"Matzen","year":"2021","journal-title":"Cardio-Oncology"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"621858","DOI":"10.3389\/fimmu.2021.621858","article-title":"Immune-Therapy-Related Toxicity Events and Dramatic Remission After a Single Dose of Pembrolizumab Treatment in Metastatic Thymoma: A Case Report","volume":"12","author":"Shen","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"ytab478","DOI":"10.1093\/ehjcr\/ytab478","article-title":"Immune checkpoint inhibitor-related myocarditis: An illustrative case series of applying the updated Cardiovascular Magnetic Resonance Lake Louise Criteria","volume":"6","author":"Wintersperger","year":"2022","journal-title":"Eur. Heart J. Case Rep."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1536\/ihj.21-653","article-title":"Asymptomatic Myocarditis with Mild Cardiac Marker Elevation Following Nivolumab-Induced Myositis","volume":"63","author":"Shindo","year":"2022","journal-title":"Int. Heart J."},{"key":"ref_94","first-page":"63","article-title":"Fatal autoimmune storm after a single cycle of anti-PD-1 therapy: A case of lethal toxicity but pathological complete response in metastatic lung adenocarcinoma","volume":"15","author":"Peinado","year":"2022","journal-title":"Hematol. Stem Cell Ther."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"424","DOI":"10.21037\/atm-22-1284","article-title":"Severe immune-related hepatitis and myocarditis caused by PD-1 inhibitors in the treatment of triple-negative breast cancer: A case report","volume":"10","author":"Yang","year":"2022","journal-title":"Ann. Transl. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2169\/internalmedicine.7644-21","article-title":"Durvalumab-associated Late-onset Myocarditis Successfully Treated with Corticosteroid Therapy","volume":"61","author":"Maetani","year":"2022","journal-title":"Intern. Med."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Nishimura, T., Ninomiya, K., Nakashima, M., Akagi, S., Kuribayashi, T., Higo, H., Hotta, K., Maeda, Y., Ito, H., and Kiura, K. (Intern. Med., 2022). Fulminant Myocarditis for Non-small-cell Carcinoma of the Lung with Nivolumab and Ipilimumab Plus Chemotherapy: A Case Report, Intern. Med., online ahead of print.","DOI":"10.2169\/internalmedicine.0505-22"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e31873","DOI":"10.1097\/MD.0000000000031873","article-title":"Severe cardiotoxicity in 2 patients with thymoma receiving immune checkpoint inhibitor therapy: A case report","volume":"101","author":"Liu","year":"2022","journal-title":"Medicine"},{"key":"ref_99","first-page":"4042909","article-title":"Camrelizumab-Related Lethal Arrhythmias and Myasthenic Crisis in a Patient with Metastatic Thymoma","volume":"2022","author":"Zhang","year":"2022","journal-title":"Case Rep. Cardiol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40959-020-00076-6","article-title":"Severe combined cardiac and neuromuscular toxicity from immune checkpoint blockade: An institutional case series","volume":"6","author":"Arora","year":"2020","journal-title":"Cardio-Oncology"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"950801","DOI":"10.3389\/fmed.2022.950801","article-title":"Myocarditis and myositis\/myasthenia gravis overlap syndrome induced by immune checkpoint inhibitor followed by esophageal hiatal hernia: A case report and review of the literature","volume":"9","author":"Yin","year":"2022","journal-title":"Front. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"778185","DOI":"10.3389\/fonc.2021.778185","article-title":"Camrelizumab-Related Myocarditis and Myositis With Myasthenia Gravis: A Case Report and Literature Review","volume":"11","author":"Bai","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1053370","DOI":"10.3389\/fonc.2022.1053370","article-title":"Acetylcholine receptor binding antibody\u2013associated myasthenia gravis, myocarditis, and rhabdomyolysis induced by tislelizumab in a patient with colon cancer: A case report and literature review","volume":"12","author":"Wang","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"955527","DOI":"10.3389\/fcvm.2022.955527","article-title":"Immune myocarditis related to sintilimab treatment in a patient with advanced lung adenocarcinoma: A case report","volume":"9","author":"Lin","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jaccas.2019.11.080","article-title":"Myocardial and Pericardial Toxicity Associated With Immune Checkpoint Inhibitors in Cancer Patients","volume":"2","author":"Chahine","year":"2020","journal-title":"JACC Case Rep."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"954468","DOI":"10.3389\/fonc.2022.954468","article-title":"Urinary incontinence as a possible signal of neuromuscular toxicity during immune checkpoint inhibitor treatment: Case report and retrospective pharmacovigilance study","volume":"12","author":"Hu","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jaccao.2020.10.013","article-title":"Immune Checkpoint Inhibitor-Associated Myocarditis With Persistent Troponin Elevation Despite Abatacept and Prolonged Immunosuppression","volume":"2","author":"Liu","year":"2020","journal-title":"JACC Cardio-Oncology"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"987345","DOI":"10.3389\/fimmu.2022.987345","article-title":"Case report: A successful re-challenge report of GLS-010 (Zimberelimab), a novel fully humanized mAb to PD-1, in a case of recurrent endometrial cancer","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"100442","DOI":"10.1016\/j.ensci.2022.100442","article-title":"Checkpoint inhibitor induced myositis\u2013The value of MRI STIR","volume":"30","author":"Scheie","year":"2023","journal-title":"Eneurologicalsci"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1080\/0284186X.2019.1711174","article-title":"Immune checkpoint inhibitor-induced myocarditis not visible with cardiac magnetic resonance imaging but detected with PET-CT: A case report","volume":"59","author":"Arponen","year":"2020","journal-title":"Acta Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"5314","DOI":"10.3389\/fimmu.2021.799077","article-title":"Case Report: Glucocorticoid Effect Observation in a Ureteral Urothelial Cancer Patient With ICI-Associated Myocarditis and Multiple Organ Injuries","volume":"12","author":"Hu","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e318","DOI":"10.3324\/haematol.2017.185777","article-title":"Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: The role of occult pre-existing autoimmunity","volume":"103","author":"Villar","year":"2018","journal-title":"Haematologica"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"bcr2016216228","DOI":"10.1136\/bcr-2016-216228","article-title":"Suspected autoimmune myocarditis and cardiac conduction abnormalities with nivolumab therapy for non-small cell lung cancer","volume":"2016","author":"Gibson","year":"2016","journal-title":"BMJ Case Rep."},{"key":"ref_114","first-page":"761","article-title":"Complete heart block and subsequent sudden cardiac death from immune checkpoint inhibitor\u2013associated myocarditis","volume":"6","author":"Giancaterino","year":"2020","journal-title":"Heart Case Rep."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"714460","DOI":"10.3389\/fcvm.2021.714460","article-title":"Case Report: The Neuromusclar Triad of Immune Checkpoint Inhibitors: A Case Report of Myositis, Myocarditis, and Myasthenia Gravis Overlap Following Toripalimab Treatment","volume":"8","author":"Luo","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"e229963","DOI":"10.1136\/bcr-2019-229963","article-title":"Nivolumab-induced myocarditis complicated by complete atrioventricular block in a patient with metastatic non-small cell lung cancer","volume":"12","author":"Tan","year":"2019","journal-title":"BMJ Case Rep."},{"key":"ref_117","first-page":"e8093","article-title":"A Case of Acute Heart Failure Following Immunotherapy for Metastatic Lung Cancer","volume":"12","author":"Parker","year":"2020","journal-title":"Cureus"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1159\/000498985","article-title":"Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature","volume":"12","author":"Agrawal","year":"2019","journal-title":"Case Rep. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.21037\/tcr-21-470","article-title":"Pembrolizumab-induced autoimmune Stevens-Johnson syndrome\/toxic epidermal necrolysis with myositis and myocarditis in a patient with esophagogastric junction carcinoma: A case report","volume":"10","author":"Cao","year":"2021","journal-title":"Transl. Cancer Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"101145","DOI":"10.1016\/j.eucr.2020.101145","article-title":"Simultaneous pembrolizumab-induced myasthenia gravis and myocarditis in a patient with metastatic bladder cancer: A case report","volume":"31","author":"Takai","year":"2020","journal-title":"Urol. Case Rep."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e010633","DOI":"10.1161\/CIRCIMAGING.120.010633","article-title":"Monitoring of the Evolution of Immune Checkpoint Inhibitor Myocarditis With Cardiovascular Magnetic Resonance","volume":"13","author":"Sato","year":"2020","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"561083","DOI":"10.3389\/fimmu.2020.561083","article-title":"Case Report: Simultaneous Hyperprogression and Fulminant Myocarditis in a Patient With Advanced Melanoma Following Treatment With Immune Checkpoint Inhibitor Therapy","volume":"11","author":"Barham","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"360","DOI":"10.21037\/tlcr.2020.02.05","article-title":"Nivolumab resulting in persistently elevated troponin levels despite clinical remission of myocarditis and myositis in a patient with malignant pleural mesothelioma: Case report","volume":"9","author":"Lie","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_124","first-page":"yty149","article-title":"Myocarditis with checkpoint inhibitor immunotherapy: Case report of late gadolinium enhancement on cardiac magnetic resonance with pathology correlate","volume":"3","author":"Gallegos","year":"2019","journal-title":"Eur. Heart J. Case Rep."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ehjcr\/ytaa214","article-title":"A different type of acute myocarditis: A case report of acute autoimmune myocarditis mediated by anti-PD-1 T lymphocyte receptor (pembrolizumab)","volume":"4","author":"Iniesta","year":"2020","journal-title":"Eur. Heart J. Case Rep."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"995121","DOI":"10.3389\/fimmu.2022.995121","article-title":"Sintilimab induced ICIAM in the treatment of advanced HCC: A case report and analysis of research progress","volume":"13","author":"Ji","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/cas.12961","article-title":"Myasthenic crisis and polymyositis induced by one dose of nivolumab","volume":"107","author":"Kimura","year":"2016","journal-title":"Cancer Sci."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"e01177","DOI":"10.1213\/XAA.0000000000001177","article-title":"Unanticipated Myocarditis in a Surgical Patient Treated With Pembrolizumab: A Case Report","volume":"14","author":"Nierstedt","year":"2020","journal-title":"A A Pract."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1056\/NEJMc1903064","article-title":"Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy","volume":"380","author":"Esfahani","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3747\/co.26.4381","article-title":"Fatal Myocarditis and Rhabdomyositis in a Patient with Stage Iv Melanoma Treated with Combined Ipilimumab and Nivolumab","volume":"26","author":"Saibil","year":"2019","journal-title":"Curr. Oncol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"ytab342","DOI":"10.1093\/ehjcr\/ytab342","article-title":"A case report of immune checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like myositis treated with abatacept and mycophenolate mofetil","volume":"5","author":"Jespersen","year":"2021","journal-title":"Eur. Heart J. Case Rep."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.2169\/internalmedicine.0255-17","article-title":"Complete Atrioventricular Block Associated with Pembrolizumab-induced Acute Myocarditis: The Need for Close Cardiac Monitoring","volume":"57","author":"Katsume","year":"2018","journal-title":"Intern. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"727445","DOI":"10.3389\/fcvm.2021.727445","article-title":"Case Report: Cardiac Toxicity Associated With Immune Checkpoint Inhibitors","volume":"8","author":"Chen","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.3389\/fcvm.2021.797009","article-title":"Sintilimab-Induced Myocarditis Overlapping Myositis in a Patient With Metastatic Thymoma: A Case Report","volume":"8","author":"Yang","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1200\/PO.20.00370","article-title":"Recurrent Myocarditis Induced by Immune-Checkpoint Inhibitor Treatment Is Accompanied by Persistent Inflammatory Markers Despite Immunosuppressive Treatment","volume":"5","author":"Aghel","year":"2021","journal-title":"JCO Precis. Oncol."},{"key":"ref_136","first-page":"497","article-title":"Immune checkpoint inhibitor\u2013mediated myocarditis and ventricular tachycardia storm","volume":"5","author":"McDowall","year":"2019","journal-title":"Heart Case Rep."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"682262","DOI":"10.3389\/fimmu.2021.682262","article-title":"Immune Myocarditis Overlapping With Myasthenia Gravis Due to Anti-PD-1 Treatment for a Chordoma Patient: A Case Report and Literature Review","volume":"12","author":"Liang","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/jmv.21962","article-title":"A novel real-time PCR system for simultaneous detection of human viruses in clinical samples from patients with uncertain diagnoses","volume":"83","author":"Katano","year":"2010","journal-title":"J. Med. Virol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1536\/ihj.20-162","article-title":"A Fatal Case of Myocarditis Following Myositis Induced by Pembrolizumab Treatment for Metastatic Upper Urinary Tract Urothelial Carcinoma","volume":"61","author":"Matsui","year":"2020","journal-title":"Int. Heart J."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"ytab262","DOI":"10.1093\/ehjcr\/ytab262","article-title":"Acute cardiac manifestations under immune checkpoint inhibitors\u2014Beware of the obvious: A case report","volume":"5","author":"Arangalage","year":"2021","journal-title":"Eur. Heart J. Case Rep."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"4695","DOI":"10.3389\/fonc.2022.961266","article-title":"PD-1 inhibitor therapy causes multisystem immune adverse reactions: A case report and literature review","volume":"12","author":"Yin","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"247","DOI":"10.21037\/atm.2019.04.73","article-title":"Successful therapy for autoimmune myocarditis with pembrolizumab treatment for nasopharyngeal carcinoma","volume":"7","author":"Wang","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jaccas.2019.12.045","article-title":"A Fatal Case of Pembrolizumab-Induced Myocarditis in Non\u2013Small Cell Lung Cancer","volume":"2","author":"Cohen","year":"2020","journal-title":"JACC Case Rep."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"e236357","DOI":"10.1136\/bcr-2020-236357","article-title":"Atezolizumab-induced myositis and myocarditis in a patient with metastatic urothelial carcinoma","volume":"13","author":"Sessums","year":"2020","journal-title":"BMJ Case Rep."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"871542","DOI":"10.3389\/fimmu.2022.871542","article-title":"Case Report: Multiple Causes of Cardiac Death After the First Infusion of Atezolizumab: Histopathological and Immunohistochemical Findings","volume":"13","author":"Kushnareva","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.3389\/fcvm.2022.898756","article-title":"Successful Therapy for Myocarditis Concomitant With Complete Heart Block After Pembrolizumab Treatment for Head and Neck Squamous Cell Carcinoma: A Case Report With Literature Review","volume":"9","author":"Su","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"e232920","DOI":"10.1136\/bcr-2019-232920","article-title":"Immune checkpoint inhibitor-mediated myasthenia gravis with focal subclinical myocarditis progressing to symptomatic cardiac disease","volume":"13","author":"Leaver","year":"2020","journal-title":"BMJ Case Rep."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1002\/ehf2.13545","article-title":"Keeping immune checkpoint inhibitor myocarditis in check: Advanced circulatory mechanical support as a bridge to recovery","volume":"8","author":"Hsu","year":"2021","journal-title":"ESC Heart Fail."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s40425-018-0473-0","article-title":"Myocarditis in a patient treated with Nivolumab and PROSTVAC: A case report","volume":"6","author":"Monge","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_150","first-page":"1851","article-title":"Case Report: Acute Myocarditis Due to PD-L1 Inhibitor Durvalumab Monotherapy in a Patient With Lung Squamous Cell Carcinoma","volume":"9","author":"Zhou","year":"2022","journal-title":"Front. Med."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"770631","DOI":"10.3389\/fphar.2021.770631","article-title":"Case Series of Steroid-Resistant Immune Checkpoint Inhibitor Associated Myocarditis: A Comparative Analysis of Corticosteroid and Tofacitinib Treatment","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Komatsu, M., Hirai, M., Kobayashi, K., Hashidate, H., Fukumoto, J., Sato, A., Usuda, H., Tanaka, K., Takahashi, K., and Kuwabara, S. (2021). A rare case of nivolumab-related myasthenia gravis and myocarditis in a patient with metastatic gastric cancer. BMC Gastroenterol., 21.","DOI":"10.1186\/s12876-021-01904-4"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1036603","DOI":"10.3389\/fcvm.2022.1036603","article-title":"Multisystem immune-related adverse events due to toripalimab: Two cases-based review","volume":"9","author":"Chen","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.cjco.2022.03.007","article-title":"A Case of Lung Cancer with Very-Late-Onset Immune Checkpoint Inhibitor-Related Myocarditis","volume":"4","author":"Nishikawa","year":"2022","journal-title":"CJC Open"},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Deharo, F., Carvelli, J., Cautela, J., Garcia, M., Sarles, C., de Paula, A.M., Bourenne, J., Gainnier, M., and Bichon, A. (2022). Immune Checkpoint Inhibitor-Induced Myositis\/Myocarditis with Myasthenia Gravis-like Misleading Presentation: A Case Series in Intensive Care Unit. J. Clin. Med., 11.","DOI":"10.3390\/jcm11195611"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2169\/internalmedicine.5317-20","article-title":"The Cytokine Expression in Patients with Cardiac Complication after Immune Checkpoint Inhibitor Therapy","volume":"60","author":"Tsuruda","year":"2021","journal-title":"Intern. Med."},{"key":"ref_157","first-page":"e18040","article-title":"Nivolumab-Induced Myasthenia Gravis Concomitant With Myocarditis, Myositis, and Hepatitis","volume":"13","author":"Bawek","year":"2021","journal-title":"Cureus"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jaccas.2019.12.047","article-title":"Immune Checkpoint Inhibitor-Associated Myocarditis","volume":"2","author":"Chatzantonis","year":"2020","journal-title":"JACC Case Rep."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.jaccas.2022.04.020","article-title":"Checkpoint Immunotherapy-Induced Myocarditis and Encephalitis Complicated With Complete AV Block","volume":"4","author":"Ruiz","year":"2022","journal-title":"JACC Case Rep."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"793","DOI":"10.21037\/apm-20-2449","article-title":"Immune checkpoint inhibitor-induced myocarditis in lung cancer patients: A case report of sintilimab-induced myocarditis and a review of the literature","volume":"10","author":"Bi","year":"2021","journal-title":"Ann. Palliat. Med."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.21037\/cdt-21-147","article-title":"Checkpoint inhibitor-induced fulminant myocarditis, complete atrioventricular block and myasthenia gravis\u2014A case report","volume":"11","author":"Clemente","year":"2021","journal-title":"Cardiovasc. Diagn. Ther."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jaccas.2019.11.076","article-title":"Evolution of Immune Checkpoint Blockade\u2013Induced Myocarditis Over 2 Years","volume":"2","author":"Norwood","year":"2020","journal-title":"JACC Case Rep."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1002\/ehf2.13912","article-title":"Fulminant myocarditis caused by immune checkpoint inhibitor: A case report and possible treatment inspiration","volume":"9","author":"Liu","year":"2022","journal-title":"ESC Heart Fail."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"884776","DOI":"10.3389\/fphar.2022.884776","article-title":"Immune Checkpoint Inhibitor-Related Myositis Overlapping With Myocarditis: An Institutional Case Series and a Systematic Review of Literature","volume":"13","author":"Nakagomi","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.amjms.2021.04.018","article-title":"Successful Treatment of Steroid-Refractory Checkpoint Inhibitor Myocarditis with Globulin Derived-Therapy: A Case Report and Literature Review","volume":"362","author":"Barry","year":"2021","journal-title":"Am. J. Med. Sci."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"03000605221133259","DOI":"10.1177\/03000605221133259","article-title":"Teriprizumab-induced myocarditis in a patient with cholangiocarcinoma: A case report","volume":"50","author":"Ye","year":"2022","journal-title":"J. Int. Med. Res."},{"key":"ref_167","first-page":"bcr-2017","article-title":"New drugs and new toxicities: Pembrolizumab-induced myocarditis","volume":"2018","author":"Inayat","year":"2018","journal-title":"BMJ Case Rep."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"944013","DOI":"10.3389\/fimmu.2022.944013","article-title":"Case Report: Treatment for steroid-refractory immune-related myocarditis with tofacitinib","volume":"13","author":"Xing","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.annonc.2020.05.005","article-title":"Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis","volume":"31","author":"Doms","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1515\/med-2022-0611","article-title":"Pacemakers and methylprednisolone pulse therapy in immune-related myocarditis concomitant with complete heart block","volume":"17","author":"Hu","year":"2022","journal-title":"Open Med."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.2169\/internalmedicine.2596-18","article-title":"Nivolumab-induced Myocarditis Successfully Treated with Corticosteroid Therapy: A Case Report and Review of the Literature","volume":"58","author":"Matsuo","year":"2019","journal-title":"Intern. Med."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.2169\/internalmedicine.9161-21","article-title":"An Autopsy Case of Late-onset Fulminant Myocarditis Induced by Nivolumab in Gastric Cancer","volume":"61","author":"Naganuma","year":"2022","journal-title":"Intern. Med."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40425-015-0057-1","article-title":"Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma","volume":"3","author":"Balmelli","year":"2015","journal-title":"J. Immunother. Cancer"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1186\/s13256-021-03097-6","article-title":"Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: A case report","volume":"15","author":"Miyauchi","year":"2021","journal-title":"J. Med. Case Rep."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1002\/ehf2.13915","article-title":"Subtle-but-smouldering myocardial injury after immune checkpoint inhibitor treatment accompanied by amyloid deposits","volume":"9","author":"Ida","year":"2022","journal-title":"ESC Heart Fail."},{"key":"ref_176","first-page":"e26034","article-title":"Pembrolizumab-Induced Myocarditis and Pancreatitis in a Patient With Colon Cancer: A Case Report","volume":"14","author":"Abdelmottaleb","year":"2022","journal-title":"Cureus"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.gore.2018.05.014","article-title":"Myocarditis with tremelimumab plus durvalumab combination therapy for endometrial cancer: A case report","volume":"25","author":"Mahmood","year":"2018","journal-title":"Gynecol. Oncol. Rep."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.2169\/internalmedicine.8772-21","article-title":"Nivolumab-induced Myositis and Myocarditis with Positive Anti-titin Antibody and Anti-voltage-gated Potassium Channel Kv1.4 Antibody","volume":"61","author":"Ono","year":"2022","journal-title":"Intern. Med."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ehjcr\/ytaa051","article-title":"Checkpoint inhibitor-induced myocarditis and myasthenia gravis in a recurrent\/metastatic thymic carcinoma patient: A case report","volume":"4","author":"Szuchan","year":"2020","journal-title":"Eur. Heart J. Case Rep."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.cjco.2022.07.002","article-title":"Myocarditis Following Immune Checkpoint Inhibition With Pembrolizumab: Management in a Context of Steroid Intolerance","volume":"4","author":"Onderko","year":"2022","journal-title":"CJC Open"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1253\/circj.CJ-22-0613","article-title":"Acute Myocarditis After Discontinuation of Immune Checkpoint Inhibitor Therapy","volume":"87","author":"Tamura","year":"2023","journal-title":"Circ. J."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.2169\/internalmedicine.8575-21","article-title":"Sinus Node Dysfunction Co-occurring with Immune Checkpoint Inhibitor-associated Myocarditis","volume":"61","author":"Nishikawa","year":"2022","journal-title":"Intern. Med."},{"key":"ref_183","first-page":"486","article-title":"Fatal myocarditis after the first dose of nivolumab","volume":"6","author":"Zomborska","year":"2022","journal-title":"Klin. Onkol."},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Czarnecka, A.M., Kleibert, M., P\u0142achta, I., Rogala, P., W\u0105grodzki, M., Leszek, P., and Rutkowski, P. (2022). Myocarditis Induced by Immunotherapy in Metastatic Melanoma\u2014Review of Literature and Current Guidelines. J. Clin. Med., 11.","DOI":"10.3390\/jcm11175182"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"614997","DOI":"10.3389\/fcvm.2021.614997","article-title":"Early Detection of Checkpoint Inhibitor-Associated Myocarditis Using 68Ga-FAPI PET\/CT","volume":"8","author":"Finke","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jaccao.2022.08.013","article-title":"Delayed Diagnosis and Recovery of Fulminant Immune Checkpoint Inhibitor-Associated Myocarditis on VA-ECMO Support","volume":"4","author":"Ramayya","year":"2022","journal-title":"JACC Cardio-Oncology"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s13256-021-02858-7","article-title":"Durvalumab-induced myocarditis, myositis, and myasthenia gravis: A case report","volume":"15","author":"Cham","year":"2021","journal-title":"J. Med. Case Rep."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"e402","DOI":"10.1093\/oncolo\/oyac033","article-title":"Consider Myocarditis When Patients Treated with Immune Checkpoint Inhibitors Present with Ocular Symptoms","volume":"27","author":"Rhee","year":"2022","journal-title":"Oncologist"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s12471-021-01655-7","article-title":"Immune checkpoint inhibitor\u2013associated myocarditis","volume":"30","author":"Osinga","year":"2022","journal-title":"Neth. Heart J."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jaccao.2022.04.007","article-title":"Late-Onset Immunotherapy-Induced Myocarditis 2 Years After Checkpoint Inhibitor Initiation","volume":"4","author":"Nguyen","year":"2022","journal-title":"JACC Cardio-Oncology"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jaccao.2019.07.004","article-title":"Immune-Checkpoint Inhibitor-Induced Fulminant Myocarditis and Cardiogenic Shock","volume":"1","author":"Nohria","year":"2019","journal-title":"JACC Cardio-Oncology"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"e004699","DOI":"10.1136\/jitc-2022-004699","article-title":"Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: Proof of concept","volume":"10","author":"Nguyen","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_193","first-page":"54","article-title":"Immune Checkpoint Inhibitor\u2013Related Myocarditis: Recognition, Surveillance, and Management","volume":"26","author":"Kuhnly","year":"2022","journal-title":"Clin. J. Oncol. Nurs."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"8512","DOI":"10.21037\/apm-20-2620","article-title":"Myocarditis related to immune checkpoint inhibitors treatment: Two case reports and literature review","volume":"10","author":"Chen","year":"2021","journal-title":"Ann. Palliat. Med."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"e002879","DOI":"10.1136\/jitc-2021-002879","article-title":"Nivolumab-associated DRESS in a genetic susceptible individual","volume":"9","author":"Ai","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40425-016-0152-y","article-title":"Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy","volume":"4","author":"Heinzerling","year":"2016","journal-title":"J. Immunother. Cancer"},{"key":"ref_197","doi-asserted-by":"crossref","unstructured":"Shalata, W., Abu-Salman, A., Steckbeck, R., Jacob, B.M., Massalha, I., and Yakobson, A. (2021). Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review. Cancers, 13.","DOI":"10.3390\/cancers13205218"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40425-016-0117-1","article-title":"Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors\u2014An autopsy study","volume":"4","author":"Koelzer","year":"2016","journal-title":"J. Immunother. Cancer"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/onco.13931","article-title":"Immune Checkpoint Inhibitor\u2013Induced Myocarditis with Myositis\/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases","volume":"26","author":"Pathak","year":"2021","journal-title":"Oncologist"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/art.41604","article-title":"Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors","volume":"73","author":"Aldrich","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","article-title":"Myocarditis in the Setting of Cancer Therapeutics","volume":"140","author":"Bonaca","year":"2019","journal-title":"Circulation"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.jaccao.2022.06.008","article-title":"What Is the Evidence of the Diagnostic Criteria and Screening of Immune Checkpoint Inhibitor\u2013Induced Myocarditis?","volume":"4","author":"Thuny","year":"2022","journal-title":"JACC Cardio-Oncology"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: An International Cardio-Oncology Society (IC-OS) consensus statement","volume":"43","author":"Herrmann","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.jacc.2009.02.007","article-title":"Cardiovascular Magnetic Resonance in Myocarditis: A JACC White Paper","volume":"53","author":"Friedrich","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/cvr\/cvz026","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"115","author":"Hu","year":"2019","journal-title":"Cardiovasc. Res."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1016\/j.transproceed.2018.08.044","article-title":"Acute Cellular Rejection and Infection Rates in Alemtuzumab vs Traditional Induction Therapy Agents for Lung and Heart Transplantation: A Systematic Review and Meta-analysis","volume":"50","author":"Li","year":"2018","journal-title":"Transplant. Proc."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"101478","DOI":"10.1016\/j.cpcardiol.2022.101478","article-title":"Electrocardiographic Features of Immune Checkpoint Inhibitor-Associated Myocarditis","volume":"2","author":"Song","year":"2023","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11912-021-01070-6","article-title":"Cardiotoxicity of Immune Checkpoint Inhibitors","volume":"23","author":"Patel","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity","volume":"19","author":"Lyon","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1080\/14740338.2021.1906860","article-title":"How can we manage the cardiac toxicity of immune checkpoint inhibitors?","volume":"6","author":"Poto","year":"2021","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1634\/theoncologist.2017-0452","article-title":"Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients","volume":"23","author":"Sarocchi","year":"2018","journal-title":"Oncol."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"4703","DOI":"10.15829\/1560-4071-2021-4703","article-title":"\u0421onsensus statement of Russian experts on the prevention, diagnosis and treatment of cardiotoxicity of anticancer therapy","volume":"26","author":"Vasyuk","year":"2021","journal-title":"Russ. J. Cardiol."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/13\/7\/1243\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:03:17Z","timestamp":1760122997000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/13\/7\/1243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,25]]},"references-count":214,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["diagnostics13071243"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics13071243","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,25]]}}}